获取途径

作者

Ying Zhao Xiujing Yao Ruyue Li Xue Dong Ying Li Yintao Li

作者单位

³Ying Zhao and Xiujing Yao contributed equally to this work. ¹Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, Shandong 261000, China ⁴Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250000, China ²School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong 261000, China

刊名

Cancer Pathogenesis and Therapy

年份

2026

卷号

Vol.4 No.3

页码

241-248

ISSN

2949-7132

关键词

Carcinoma Non-small cell lung Immunotherapy Receptor Epidermal growth factor Mutation Adverse events Survival analysis

摘要

Background Although chemotherapy combined with immunotherapy is effective in advanced non-small cell lung cancer , its efficacy in patients with epidermal growth factor receptor exon 20 insertion mutations remains unclear. Methods This retrospective analysis included 66 patients: 28 received chemotherapy plus immunotherapy, and 38 received chemotherapy alone. The primary endpoint was progression-free survival , and the secondary endpoint was safety. In eligible patients with measurable disease...更多

Background Although chemotherapy combined with immunotherapy is effective in advanced non-small cell lung cancer , its efficacy in patients with epidermal growth factor receptor exon 20 insertion mutations remains unclear. Methods This retrospective analysis included 66 patients: 28 received chemotherapy plus immunotherapy, and 38 received chemotherapy alone. The primary endpoint was progression-free survival , and the secondary endpoint was safety. In eligible patients with measurable disease, tumor response was assessed using the Response Evaluation Criteria in Solid Tumors version 1.1. PFS was defined as the time from the first day of therapy to disease progression or death from any cause. Results The median progression–free survival was 10.5 months : 7.03–16.63 months) in the chemotherapy plus immunotherapy group and 6.23 months in the chemotherapy alone group. There was a significant difference in efficacy between the chemotherapy plus immunotherapy and chemotherapy-alone groups . Among the 25 patients evaluated for tumor response in the chemotherapy plus immunotherapy group, 11 achieved a partial response , 8 had stable disease , and 6 had progressive disease . The objective response rate was 44%. Adverse events included gastrointestinal reactions and myelosuppression. There were no significant differences in terms of safety between the two treatment groups. Conclusions First-line chemotherapy combined with immunotherapy was associated with significantly longer PFS than chemotherapy alone in patients with EGFR ex20ins-mutant NSCLC, without increased toxicity.收起

文献类型

期刊